FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
MWN-AI** Summary
OKYO Pharma Limited, a biopharmaceutical company focused on ophthalmology, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, urcosimod, aimed at treating neuropathic corneal pain (NCP). This designation is particularly significant as NCP is a severe ocular condition lacking FDA-approved therapies, characterized by debilitating eye pain due to nerve damage.
Fast Track designation is a status that aids in accelerating the development and review process of therapies intended for serious conditions and unmet medical needs, ultimately benefiting patients with earlier access to promising treatments. With this designation, OKYO Pharma will have the opportunity for more frequent communication with the FDA regarding the drug's development, eligibility for Accelerated Approval and Priority Review, and the possibility of a Rolling Review for its New Drug Application (NDA).
Gary S. Jacob, CEO of OKYO Pharma, expressed excitement about the milestone, stating it reinforces the company's commitment to developing innovative treatments that positively impact patient lives. Urcosimod operates as a lipid-conjugated chemerin peptide agonist, targeting immune response and pain in the ocular environment. The drug has shown promise in preclinical models and a Phase 2 clinical trial aimed at evaluating its efficacy for patients with NCP.
OKYO Pharma is dedicated to furthering the clinical development of urcosimod, addressing the considerable unmet need in pain management for patients suffering from neuropathic corneal pain. This progress underscores the company’s focus on leveraging novel therapeutic approaches in ophthalmic care, alongside its ongoing efforts for dry eye disease treatment. For more information, visit www.okyopharma.com.
MWN-AI** Analysis
OKYO Pharma Limited (NASDAQ: OKYO) recently received Fast Track designation from the FDA for its investigational drug urcosimod, aimed at treating neuropathic corneal pain (NCP). This designation carries significant implications for both patients and investors, propelling the company’s stock potential and market visibility.
Neuropathic corneal pain is a condition that severely disrupts patients' quality of life, currently lacking any FDA-approved treatment options. Given this unmet medical need, OKYO's progress with urcosimod not only positions the company as a pioneer in a critical therapeutic area but also offers the opportunity for expedited drug development pathways. The Fast Track designation allows for closer collaboration with the FDA, potential accelerated approvals, and rolling reviews of the New Drug Application (NDA), giving investors confidence in the timely advancement of urcosimod through clinical trials.
The recent success in the Phase 2 trial for NCP patients further bolsters OKYO's standing, with urcosimod showing statistically significant efficacy in reducing pain. This clinical validation enhances investor sentiment and positions OKYO favorably as it potentially prepares for broader market introduction. Given the scope for market growth, considering the absence of approved treatments, there is a strong value proposition for shareholders and a compelling case for investment.
However, investors should be cognizant of the inherent risks involved, such as the uncertainties in clinical outcomes and regulatory approvals that can impact timelines and financial metrics. As OKYO progresses through the next phases of clinical trials, keeping a close watch on FDA interactions and trial results will be critical. Overall, OKYO Pharma presents a promising investment opportunity, particularly in the context of the growing need for effective treatments in ophthalmic pain management.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic and often severe pain but without an FDA-approved therapy, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP).
Fast Track designation by the FDA is granted to facilitate the development and expedite the review of therapies that aim to treat serious conditions and fulfill unmet medical needs. This designation is intended to accelerate the availability of new treatments to patients, providing earlier access to potentially beneficial therapies. The Fast Track designation provides several key benefits, including more frequent meetings with the FDA to discuss the drug’s development plan, eligibility for Accelerated Approval and Priority Review if relevant criteria are met, and a potential Rolling Review of the New Drug Application (NDA).
Neuropathic corneal pain is a debilitating condition characterized by persistent, severe eye pain caused by nerve damage, impacting a significant number of patients worldwide. OKYO Pharma's urcosimod aims to address this urgent medical need with its innovative approach.
Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma, expressed his enthusiasm about the FDA's decision: "We are thrilled with the FDA's Fast Track designation for urcosimod in the treatment of neuropathic corneal pain. This milestone underscores our commitment to advancing innovative therapies that can make a meaningful difference in patients' lives. We look forward to working closely with the FDA to bring this promising treatment to patients as quickly as possible."
OKYO Pharma remains dedicated to advancing urcosimod through clinical development and regulatory review, with a focus on addressing the significant unmet medical need in neuropathic corneal pain treatment.
About NCP
Neuropathic corneal pain is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of neuropathic corneal pain is unknown but is thought to result from nerve damage to the cornea combined with inflammation . Neuropathic corneal pain, which can exhibit as a severe, chronic, debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated by various topical and systemic treatments in an off-label fashion. Notably, there is no FDA approved drug to treat this debilitating condition.
About the Urcosimod Phase 2 Trial in NCP Patients
The Phase 2 study was designed as a double-masked, randomized, 12-week placebo-controlled trial in NCP patients, with disease confirmed via confocal microscopy.
About Urcosimod (Formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the residence time of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and was also being evaluated in a randomized, placebo-controlled, double-masked Phase 2 trial to treat neuropathic corneal pain patients.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. In addition to the completed Phase 2 trial of urcosimod to treat dry eye disease patients, OKYO is also currently evaluating urcosimod to treat neuropathic corneal pain patients.
For further information, please visit www.okyopharma.com .
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ**
How does the FDA's Fast Track designation for OKYO Pharma Limited (OKYO) influence the potential timelines for urcosimod's approval and what implications does this have for investors?
What are the expected milestones for OKYO Pharma Limited (OKYO) as it advances urcosimod through clinical development, particularly in terms of trial results and FDA interactions?
Given the urgency of treating neuropathic corneal pain, what strategies is OKYO Pharma Limited (OKYO) employing to ensure timely access to this therapy for patients following FDA approval?
How does the innovative approach of urcosimod, as developed by OKYO Pharma Limited (OKYO), differ from existing off-label treatments for neuropathic corneal pain, and what competitive advantages might this provide?
**MWN-AI FAQ is based on asking OpenAI questions about OKYO Pharma Limited (NASDAQ: OKYO).
NASDAQ: OKYO
OKYO Trading
1.2% G/L:
$1.70 Last:
138 Volume:
$1.70 Open:
